Welcome to MS Australia
News
On Wednesday 1 May 2019, Novartis announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis.
The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
Channel 7 News reported the announcement, and spoke to our CEO Deidre...
Blog
Over my seven years of working as a support worker, I had the privilege of sharing my time with several amazing individuals who lived with Progressive MS.Reflecting upon this period in my life, I am flooded with emotions and memories of the fantastic people that I spent time with on a weekly basis.People will often quote time as the most valuable thing you can give someone, but it was perhaps something I found hard to quantify or wrap my head around, until spending time with people one-on-one...
Events
Tweets by @MS_Australia
Tweets by MS_AustraliaSupport & Services
As the national peak body for Australians living with MS, we work closely with the state MS societies to help you connect with the right support and services.